[Localization diagnostics of malignant tumors using radioactive bleomycin (author's transl)]

Total-body scintigraphy with 111In-labeled bleomycin was performed in 66 patients with malignant solid tumors and systemic diseases of the lymphatic pathways (Hodgkin's lymphoma and non-Hodgkin's lymphoma). In 38 (58%) of 66 cases positive information was correct. In 12 (18%) of 66, scintigraphic information was correctly negative. With 16 out of 66 (24%), false positive or false negative informations were obtained.